Early research (Phase 1)Ended earlyNCT01611675What this trial is testingLeflunomide+Vemurafenib in V600 Mutant Met. MelanomaWho this might be right forMelanoma Massachusetts General Hospital 3
Not applicableStudy completedNCT04961619What this trial is testingAdjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.Who this might be right forMelanoma Novartis Pharmaceuticals 39
Early research (Phase 1)Study completedNCT02608034What this trial is testingInvestigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady StateWho this might be right forMetastatic Melanoma, BRAF V600 Mutation Positive Genentech, Inc. 32
Testing effectiveness (Phase 2)Active Not RecruitingNCT02231775What this trial is testingDabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationWho this might be right forStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7 M.D. Anderson Cancer Center 58
Early research (Phase 1)Study completedNCT02729298What this trial is testingFirst-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid TumorsWho this might be right forAdvanced Solid TumorsEGFR Positive Non-small Cell Lung CancerColorectal Carcinoma+2 more Sumitomo Pharma America, Inc. 177
Testing effectiveness (Phase 2)Ended earlyNCT02052193What this trial is testingEvaluation of Photosensitivity in Dabrafenib or Vemurafenib Treated Metastatic Melanoma Patients - a Phase IIa/IIb StudyWho this might be right forMetastatic Melanoma (Carrying BRAF V600 Mutation) University Hospital Tuebingen 8
Testing effectiveness (Phase 2)Temporarily pausedNCT05756556What this trial is testingT3011 in Combination With Cobimetinib in Patients With Advanced MelanomaWho this might be right forMelanomaMalignant Melanoma ImmVira Pharma Co. Ltd 68
Early research (Phase 1)Study completedNCT01673737What this trial is testingA Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced CancerWho this might be right forNeoplasm Malignant Sanofi 75
Testing effectiveness (Phase 2)UnknownNCT02202200What this trial is testingPhase I-II Study With Tumor Molecular Pharmacodynamic (MPD) Evaluation and Pharmacokinetics of PD-0332991 in Patients Suffering Metastatic MelanomaWho this might be right forMelanoma BRAF V600E/K MutatedCDNKN2A Loss Defined Assistance Publique - Hôpitaux de Paris 40
Early research (Phase 1)Ended earlyNCT01940809What this trial is testingIpilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by SurgeryWho this might be right forBRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Melanoma+5 more National Cancer Institute (NCI) 15
Large-scale testing (Phase 3)Active Not RecruitingNCT05270044What this trial is testingAdjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.Who this might be right forMelanoma Pierre Fabre Medicament 815
Early research (Phase 1)WithdrawnNCT02357732What this trial is testingStudy of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or TrametinibWho this might be right forMetastatic Melanoma University of Pittsburgh
Testing effectiveness (Phase 2)Study completedNCT02631447What this trial is testingSequential Combo Immuno and Target Therapy (SECOMBIT) StudyWho this might be right forMetastatic Melanoma Fondazione Melanoma Onlus 251
Early research (Phase 1)Temporarily pausedNCT01841463What this trial is testingStudy of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF MutationWho this might be right forAdvanced or Inoperable Malignant Melanoma With BRAF Mutation Piramal Enterprises Limited 100
Testing effectiveness (Phase 2)Study completedNCT00936221What this trial is testingComparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma PatientsWho this might be right forMelanoma AstraZeneca 385
Early research (Phase 1)Study completedNCT01767454What this trial is testingStudy of Dabrafenib +/- Trametinib in Combination With Ipilimumab for V600E/K Mutation Positive Metastatic or Unresectable MelanomaWho this might be right forSolid Tumours GlaxoSmithKline 38
Testing effectiveness (Phase 2)Not Yet RecruitingNCT05275374What this trial is testingXP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationWho this might be right forCancerBRAF V600 MutationMelanoma+3 more Xynomic Pharmaceuticals, Inc. 221
Testing effectiveness (Phase 2)Ended earlyNCT04310397What this trial is testingDabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D MelanomaWho this might be right forPathologic Stage IIIB Cutaneous Melanoma AJCC v8Pathologic Stage IIIC Cutaneous Melanoma AJCC v8Pathologic Stage IIID Cutaneous Melanoma AJCC v8 M.D. Anderson Cancer Center 4
Early research (Phase 1)Ended earlyNCT02097225What this trial is testingOnalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryWho this might be right forBRAF V600E Mutation PresentBRAF V600K Mutation PresentMetastatic Malignant Solid Neoplasm+7 more National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT06784648What this trial is testingDifferent Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic MelanomaWho this might be right forMelanoma MetastaticMelanoma of SkinMelanoma BRAF V600E/K Mutated+7 more BioInvent International AB 35